PubMed Health⌕ Search

Biomedical subjects

P Schiff

Publications and source records attributed to P Schiff.

13 recordsLinked to original sources
PubMed1992

SPPS and hypotension.

Explore the source record for details and available documents.

Angiotensin-Converting Enzyme Inhibitors↗
PubMed1987

Decreased incidence of adverse infusion reactions in hypogammaglobulinemic children receiving low pH intravenous immunoglobulin.

Eighteen patients (ages eight months to 20 years) with disorders of immunoglobulin and antibody production received infusions of two preparations of intravenous immunoglobulin in a blind crossover trial. The incidence and severity of immediate adverse infusion reactions was significantly lower with low pH immunoglobulin; ten patients (56%) experiencing immediate reactions with the standard preparation and only one patient experiencing an immediate reaction with the low pH preparation (p less than 0.01). Infusion times were significantly less with the low pH preparation (p less than 0.02) and patient tolerance, determined by visual analogue scores, was significantly better than with the standard preparation (p less than 0.01). However, the incidence of delayed reactions (44%) was the same for both infusions.

Adolescent↗
PubMed1987

Albumin solutions--their production and quality control.

Analysis of all clinical reactions (complaints) reported to CSL in the past decade has revealed that "hypotension syndrome" continues to be the predominant side effect of infusion of albumin solutions. Although the incidence of clinical reactions to albumin solutions reported to CSL is approximately 1 in every 20,000 bottles issued, the virtual elimination of PKA from SPPS has not reduced the number of adverse clinical reports received by CSL. It is concluded that factors other than PKA contamination are responsible for hypotensive effects during or after infusion of albumin solutions. Other possible causes of "hypotension syndrome" are discussed.

Humans↗
PubMed1985

Use of heat-treated clotting-factor concentrates in patients with haemophilia and a high exposure to HTLV-III.

In a group of 126 Australian patients with haemophilia, who were receiving lyophilized clotting-factor concentrates prepared from locally collected plasma, a high prevalence of antibody to human T-cell lymphotropic virus III (HTLV-III) was demonstrated in those with severe disease. Patients with moderate or mild disease had a much lower prevalence of HTLV-III antibody. After heat treatment of lyophilized factor VIII and factor IX concentrates (60 degrees C for 72 hours) to inactivate the virus, the losses of activity of an intermediate-purity and of a fibrinogen-poor factor VIII concentrate, and of the coagulant activity of a factor IX concentrate, were within acceptable limits. The solubility of the intermediate-purity factor VIII concentrate was markedly decreased; the fibrinogen-poor factor VIII concentrate and the factor IX concentrate were readily soluble. In-vivo recovery and survival of heated concentrates were equivalent to those of the unheated products, and they were effective in the treatment of spontaneous and traumatic haemorrhages.

Acquired Immunodeficiency Syndrome↗
PubMed1977

Albumin-containing plasma volume expanders.

Human albumin-containing solutions have been used as plasma volume expanders and in the management of severe hypoproteinaemia for over 30 years; Modern indications for their use are described in some detail. These include the management of shock, burns, adult respiratory distress syndrome, and priming of the cardiopulmonary bypass pump. Reactions to albumin infusions are rare. Recent reports of hypotension following rapid infusion of SPPS and PPF are under active pharmacological study.

Adult↗
PubMedDate not supplied

Effect of virucidal heat treatment on proteins in human factor VIII concentrates.

Intermediate-purity and fibrinogen-poor factor VIII concentrates were heated in the lyophilized state at 60 degrees C for up to 72 hours to inactivate blood-borne viruses. The effect of heat treatment on factor VIII, von Willebrand factor (vWf), and other proteins present in the concentrates (albumin, fibrinogen, fibronectin, IgG, and IgM) was evaluated. Heat-induced protein aggregation, particularly of fibrinogen and fibronectin, occurred within 48 hours in the intermediate-purity concentrates and correlated well with decreased solubility of these products. Heated fibrinogen-poor concentrates were readily soluble and did not show protein aggregation even after 72 hours at 60 degrees C. Neither concentrate developed detectable neoantigens when tested against antisera to whole human plasma and to heated and unheated concentrates. Aggregation of the vWf molecule, detected by altered mobility in crossed immunoelectrophoresis and multimeric analysis in SDS agarose gels, occurred in heated intermediate-purity concentrates but not in fibrinogen-poor concentrates. Thus, higher-purity factor VIII concentrates withstand heat treatment better than concentrates that contain greater levels of contaminating proteins, particularly fibrinogen.

Chromatography, Gel↗
PubMedDate not supplied

Effect of delayed blood processing on the yield of factor VIII in cryoprecipitate and factor VIII concentrate.

Current standards for the preparation of factor VIII (FVIII) concentrates from human plasma recommend separation of plasma from red cells (RBCs) within 6 hours of blood donation, thereby reducing the volume of plasma from donated whole blood available for processing to FVIII concentrate. The decay of FVIII clotting activity (FVIII:C) in whole blood and plasma stored at 22 and 4 degrees C and the recovery of FVIII:C in cryoprecipitate and FVIII concentrate prepared from plasma separated from whole blood stored overnight at 4 degrees C were investigated. In whole blood stored at 22 degrees C and plasma stored at either 4 or 22 degrees C, 90 percent of the original FVIII:C was present at 6 hours, 80 percent at 12 hours, and 65 to 70 percent at 18 hours. At these times lower levels of FVIII:C were recovered from whole blood stored at 4 degrees C, that is, 84, 68, and 56 percent, respectively. In cryoprecipitates prepared from plasma separated from RBCs after 18 hours' storage at 4 degrees C (18-hour plasma), 43 percent of FVIII:C activity was recovered, as compared with 61 percent recovered from standard plasma separated within 6 hours of donation (6-hour plasma), p less than 0.05. With large-scale preparation of FVIII concentrates, however, the yield of FVIII:C was similar whether 18- or 6-hour plasma was used. Thus FVIII concentrates--but not cryoprecipitates--can be prepared from plasma separated from whole blood stored at 4 degrees C for up to 18 hours without undue loss of potency.

Antigens↗